ATLANTA — Bluebird Bio (BLUE) only discloses gene therapy data on its inherited blood disorder programs twice each year, so expectations — and risks — run high each time the biotech reveals its cards.
On Sunday night at the American Society of Hematology’s annual meeting, Bluebird passed the latest test. Back-to-back presentations offered strengthening evidence that its Lentiglobin gene therapy is producing significant benefits for patients with beta-thalassemia and sickle cell disease.
About the Author Reprints
